Systemic and renal hemodynamic effects of single oral doses of cadralazine and long term antihypertensive effects of cadralazine in patients receiving therapy with beta-blockers and diuretics.
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D004232:Diuretics / Q000008:administration & dosage; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D008914:Minoxidil / Q000008:administration & dosage; D011724:Pyridazines / Q000008:administration & dosage*; D012079:Renal Circulation / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004232:Diuretics; D011724:Pyridazines; D006830:Hydralazine; D008914:Minoxidil; C031877:cadralazine